Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Geron Corporation(GERN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for GERN
10/23/2026: GERN (1-star) is currently NOT-A-BUY. Pass it for now.
Geron Corporation is a clinical-stage biotech firm that has successfully transitioned into a commercial-stage company following the 2024 FDA approval of its lead drug, Rytelo. The company's main strength lies in its specialized focus on telomerase inhibition, with Rytelo serving as a critical therapeutic for transfusion-dependent MDS patients. While this commercial launch provides a clear growth path, the company faces significant competitive risk from large pharmaceutical firms with established oncology products. As a single-product company, Geron exhibits high execution risk and volatility, making it most suitable for growth-focused investors who can tolerate biotech sector exposure. Monitoring the commercial adoption rate of Rytelo is key to evaluating future performance.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit while signal remains positive | Investors looking for capital appreciation from a successful commercial launch may find the company's transition compelling. |
| Momentum investor | Mixed fit | Momentum may be influenced by commercial performance signals; conditional on positive market uptake. |
| Value investor | Weak fit | The company is not currently valued based on traditional earnings or dividend metrics. |
| Dividend investor | Weak fit | Geron does not pay a dividend, making it unsuitable for income-focused portfolios. |
| Low-risk investor | Weak fit | The company carries significant clinical and commercial execution risks typical of the biotech sector. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks are prone to sharp price swings based on clinical news or commercial data releases. |
| Valuation risk | Medium / high | Valuation is sensitive to long-term revenue projections for Rytelo which remain speculative. |
| Competition risk (oncology) | High | The company faces deep-pocketed competitors with established market presence in blood cancers. |
| Business quality | Medium | The company is shifting toward a commercial business model but lacks a diversified revenue base. |
| Dividend income | Low / none | There is no dividend payout, as all capital is needed for operations. |
| Execution risk | High | Success depends heavily on the effective commercial rollout and market penetration of Rytelo. |
Price Behavior
Downtrend
The stock has experienced a sustained decline in price over recent periods.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit -58.97% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/23/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 719.57M USD | Price to earnings Ratio - | 1Y Target Price 4.25 |
Price to earnings Ratio - | 1Y Target Price 4.25 | ||
Volume (30-day avg) 8.7M shares | Beta 0.61 | 52 Weeks Range 1.04 - 2.01 | Updated Date 10/25/2026 |
52 Weeks Range 1.04 - 2.01 | Updated Date 10/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.11 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Sales | Revenue generated from the sale of Rytelo (imetelstat) to healthcare providers and hospitals. | The company is now in the early stages of generating revenue directly from drug sales rather than just research funding. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 65.36 | Enterprise Value 659.72M | Price to Sales(TTM) 3.52 |
Enterprise Value 659.72M | Price to Sales(TTM) 3.52 | ||
Enterprise Value to Revenue 3.23 | Enterprise Value to EBITDA -9.06 | Shares Outstanding 642.47M | Shares Floating 556.31M |
Shares Outstanding 642.47M | Shares Floating 556.31M | ||
Percent Insiders 0.08 | Percent Institutions 77.03 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.